<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Usui Y</submitter><funding>Special Postdoctoral Researcher Program at RIKEN</funding><funding>The MSD Life Science Foundation</funding><funding>The Yasuda Medical Foundation</funding><funding>The Takeda Science Foundation</funding><funding>The Ministry of Education, Science, Sports, Culture, and Technology of Japan</funding><funding>Japan Agency for Medical Research and Development (AMED)</funding><pagination>298-306</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12209765</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>6(4)</volume><pubmed_abstract>Clonal hematopoiesis of indeterminate potential (CHIP) has broad clinical relevance, and TP53 plays various roles within cells. However, the gene-specific and cross-disease significance of CHIP with TP53 mutations (TP53-CHIP) remains unclear. In this study, we evaluated TP53-CHIP using targeted sequencing data of 140,597 individuals without hematologic neoplasms in BioBank Japan. We identified 1,157 individuals with TP53-CHIP and clarified the characteristics of mutations and carriers. TP53-CHIP was associated with poor overall survival, especially because of lymphoid neoplasms and respiratory disease, in addition to myeloid neoplasms. Significant interactions accompanied by excess risks were observed between TP53-CHIP and lifestyle factors for disease-specific mortality: acetaldehyde expo</pubmed_abstract><journal>Blood cancer discovery</journal><pubmed_title>Clinical Significance of TP53-Mutant Clonal Hematopoiesis Across Diseases.</pubmed_title><pmcid>PMC12209765</pmcid><funding_grant_id>24K20206</funding_grant_id><funding_grant_id>JP19kk0305010</funding_grant_id><funding_grant_id>JP18km0605001</funding_grant_id><funding_grant_id>JP22ama121015</funding_grant_id><funding_grant_id>JP23tm0624002</funding_grant_id><funding_grant_id>23K19459</funding_grant_id><funding_grant_id>JP23ck0106805</funding_grant_id><pubmed_authors>Endo M</pubmed_authors><pubmed_authors>Iwasaki Y</pubmed_authors><pubmed_authors>Momozawa Y</pubmed_authors><pubmed_authors>Iijima H</pubmed_authors><pubmed_authors>Usui Y</pubmed_authors><pubmed_authors>Matsuda K</pubmed_authors><pubmed_authors>Nakagawa H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Clinical Significance of TP53-Mutant Clonal Hematopoiesis Across Diseases.</name><description>Clonal hematopoiesis of indeterminate potential (CHIP) has broad clinical relevance, and TP53 plays various roles within cells. However, the gene-specific and cross-disease significance of CHIP with TP53 mutations (TP53-CHIP) remains unclear. In this study, we evaluated TP53-CHIP using targeted sequencing data of 140,597 individuals without hematologic neoplasms in BioBank Japan. We identified 1,157 individuals with TP53-CHIP and clarified the characteristics of mutations and carriers. TP53-CHIP was associated with poor overall survival, especially because of lymphoid neoplasms and respiratory disease, in addition to myeloid neoplasms. Significant interactions accompanied by excess risks were observed between TP53-CHIP and lifestyle factors for disease-specific mortality: acetaldehyde expo</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jul</publication><modification>2026-06-02T17:52:47.911Z</modification><creation>2026-04-18T03:11:59.137Z</creation></dates><accession>S-EPMC12209765</accession><cross_references><pubmed>40525786</pubmed><doi>10.1158/2643-3230.BCD-24-0355</doi></cross_references></HashMap>